TY  - JOUR
AU  - Hennrich, Ute
AU  - Wagner, Laurène
AU  - Tas, Harun
AU  - Kovacs, Luciana
AU  - Benesova-Schäfer, Martina
TI  - Revolutionizing Prostate Cancer Detection: The Role of Approved PSMA-PET Imaging Agents.
JO  - Pharmaceuticals
VL  - 18
IS  - 6
SN  - 1424-8247
CY  - Basel
PB  - MDPI
M1  - DKFZ-2025-01324
SP  - 906
PY  - 2025
N1  - #EA:W630#LA:E270#
AB  - Locametz®/Illuccix®/GozellixTM (Novartis AG (Basel, Switzerland) and Telix Pharmaceuticals, Ltd. (Melbourne, Australia), all three [68Ga]Ga-PSMA-11), Pylarify®/Pylclari® (Progenics Pharmaceuticals, Inc. (New York, USA) and Curium PET France SA (Paris, France), both [18F]DCFPyL), Radelumin® (ABX GmbH (Radeberg, Germany), [18F]PSMA-1007), and Posluma® (Blue Earth Diagnostics, Ltd. (Oxford, UK), [18F]rhPSMA-7.3) are four approved PSMA-PET imaging agents that have significantly advanced the diagnosis and management of prostate cancer. These agents offer a new level of precision and accuracy, enabling clinicians to detect prostate cancer with enhanced sensitivity. As a result, they play a critical role in improving detection, staging, and management, ultimately enhancing clinical outcomes for patients. Their use in routine clinical practice is expected to increase diagnostic precision and provide clearer pathways for personalized therapy. This review offers a comprehensive chemical, pharmaceutical, and medicinal overview, discusses comparative studies, and highlights additional highly relevant candidates for prostate cancer detection.
KW  - EMA approval (Other)
KW  - FDA approval (Other)
KW  - GozellixTM (Other)
KW  - Illuccix® (Other)
KW  - Locametz® (Other)
KW  - PET diagnostics (Other)
KW  - PSMA (Other)
KW  - Posluma® (Other)
KW  - Pylarify® (Other)
KW  - Pylclari® (Other)
KW  - Radelumin® (Other)
KW  - fluorine-18 (Other)
KW  - gallium-68 (Other)
KW  - prostate cancer (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:40573302
DO  - DOI:10.3390/ph18060906
UR  - https://inrepo02.dkfz.de/record/302329
ER  -